Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Ambalal Sarabhai Enterprises is currently trading at upper circuit of Rs. 12.43, up by 2.07 points or 19.98% from its previous closing of Rs. 10.36 on the BSE.
The scrip opened at Rs. 11.85 and has touched a high and low of Rs. 12.43 and Rs. 11.25 respectively. So far 75069 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 16.45 on 10-Apr-2019 and a 52 week low of Rs. 9.05 on 16-Oct-2019.
Last one week high and low of the scrip stood at Rs. 12.45 and Rs. 10.01 respectively. The current market cap of the company is Rs. 95.26 crore.
The promoters holding in the company stood at 30.76%, while Institutions and Non-Institutions held 0.01% and 69.24% respectively.
CoSara Diagnostics, a joint venture company of Co-Diagnostics Inc., USA and a Synbiotics, a wholly owned subsidiary of Ambalal Sarabhai Enterprises, has obtained regulatory clearance for five tests to be manufactured and sold as in vitro diagnostics (IVDs) from their facility in Ranoli India.
The test for Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis C and human papillomavirus (HPV) meet the requirements of the Central Drug Standard Control Organization (CDSCO) Medical Device Rules (MDR), 2017.
Regulatory clearance allows CoSara for the first time to manufacture and sell the test for the detection of the respective pathogens and microorganisms.
Ambalal Sarabhai Enterprises is engaged in manufacturing and marketing of pharmaceutical products, bulk drugs, industrial chemicals, detergents, toiletries, electronics, engineering products, paper, glass and plastic containers and packaging materials.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1531.05 |
| Dr. Reddys Lab | 6428.05 |
| Cipla | 1482.30 |
| Zydus Lifesciences | 1093.45 |
| Lupin | 1637.60 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
